In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) were not associated with a higher risk of acute pancreatitis than placebo.
In plain wordsIn adults with type 2 diabetes, the drug class that includes liraglutide did not raise the risk of acute pancreatitis compared with placebo.
- Peptide
- Liraglutide
- Outcome
- No significant changeAcute pancreatitis risk
- Study
n = 18,700
- Comparator
- Placebo
- Outcome group
- Adverse events · Gastrointestinal
Measurements
- Peto odds ratio
- 0.745 ratio
- GLP-1RA vs placebo
Source sentences
Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]).
2 context sentences(design, population, supporting numbers)
We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees.
Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.